[Impact of cryopreservation duration of 605 units umbilical cord blood on quality of hematopoietic stem cell and outcome of clinical transplantation]

Zhonghua Xue Ye Xue Za Zhi. 2015 Jan;36(1):1-3. doi: 10.3760/cma.j.issn.0253-2727.2015.01.001.
[Article in Chinese]

Abstract

Objective: To investigate the impact of cryopreservation duration of umbilical cord blood (UCB) on quality of hematopoietic stem cell and outcome of clinical transplantation.

Methods: 605 units of UCB which had been used in clinical transplantation were previously cryopreserved for 820 (88-2651) days in average. UCB was detected for total nucleated cell count, CD34+ cells count, cell recovery rate, cell viability and CFU-GM after thawing.

Results: No statistical correlation was found between cryopreservation duration and cell recovery rate, cell viability. CFU-GM decreased along with the extension of cryopreservation duration (P=0.011), ranging between 109.6 and 105.7/1 × 10⁵. There was no significant difference on hematopoietic reconstitution time, graft failure, acute GVHD and overall survival among groups with different cryopreservation duration.

Conclusion: Cryopreservation duration has no significant effect on cell recovery rate, cell viability and clinical transplantation outcome. Extension of cryopreservation duration may reduce CFU-GM of stem cells with fluctaion still in normal range. UCB could maintain cell viability and function to achieve satisfactory clinical transplantation outcome even when thawed after 3 to 7 years' cryopreservation.

目的: 探讨液氮冻存时间对脐血造血干细胞质量和临床移植效果的影响。

方法: 对上海脐血库已经应用于临床移植的605份脐血进行研究,脐血平均冻存时间为820(88~2651)d,测定脐血复苏之后的有核细胞、CD34+细胞数量、细胞回收率、细胞活力,粒-单核细胞集落形成单位(CFU-GM),结合脐血冻存时间、临床移植效果进行统计分析。

结果: 复苏后细胞回收率、细胞活力与冻存时间无显著相关性,CFU-GM平均(109.6~105.7)个/1×105,随冻存时间延长逐渐降低(P=0.011)。临床移植患者的造血重建时间、植入失败率、急性移植物抗宿主病、总体生存率与脐血冻存时间长短无显著相关性。

结论: 深低温冻存时间长短对脐血复苏后细胞回收率、细胞活力、临床移植效果无显著影响,冻存时间较长的脐血复苏后CFU-GM在正常标准范围内略有下降,保存3~7年的脐血仍能维持正常细胞活性和功能、达到良好的临床移植效果。

MeSH terms

  • Cell Count
  • Cell Survival
  • Cryopreservation
  • Fetal Blood*
  • Graft vs Host Disease
  • Granulocyte-Macrophage Progenitor Cells
  • Hematopoietic Stem Cell Transplantation*
  • Hematopoietic Stem Cells*
  • Humans
  • Treatment Outcome

Grants and funding

基金项目:上海市科技成果转化与产业化项目(12431902202);上海市科技小巨人(培育)企业项目(13HX11810000)